NDA 022138 · Sanofi Aventis US
Lovenox
Enoxaparin Sodium · Injection
Priority reviewLast checked: Nov 20, 2026Latest source record: May 16, 2007 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2007
May 16, 2007
Approved uses
1
Original approval plus efficacy supplements
Registered trials
421
139 Phase 3, 34 recruiting
FAERS reports
58,051
50,417 serious, 8,973 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 16, 2007 Original approval · Type 6 - New Indication (no longer used) · priority review LabelReviewOther Important Information from FDA
1 products under this application
- LOVENOX · ENOXAPARIN SODIUM 100MG/ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Enoxaparin" as an intervention, any sponsor and status, largest first.
- Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment Thrombolysis in Myocardial Infarction - Study 25 (ExTRACT-TIMI25)Pivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00077792 · 20,506 participants · Start Oct 2002 · Primary completion Dec 2006
Drug: Enoxaparin sodium (XRP4563) · For: Myocardial Infarction; Acute ST-Segment Elevation
Sites: Bridgewater, New Jersey; Buenos Aires, Argentina; Macquarie Park, Australia · 48 sites in all
- Michelangelo - Oasis 5Pivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT00139815 · 20,078 participants · Start Apr 2003 · Primary completion Dec 2005
Drug: Fondaparinux; enoxaparin · For: Thromboembolism
- Comparison of Angiomax Versus Heparin in Acute Coronary Syndromes (ACS)Pivotal-lookingCompleted
The Medicines CompanyIndustry
NCT00093158 · 13,800 participants · Start Aug 2003
Drug: Angiomax (bivalirudin) anticoagulant · For: Unstable Angina; Myocardial Infarction; Acute Disease
Sites: New York, New York
- PREVENTion of Clot in Orthopaedic TraumaPivotal-lookingCompleted
Major Extremity Trauma Research ConsortiumAcademic, hospital or other
NCT02984384 · 12,424 participants · Start Apr 24, 2017 · Primary completion Feb 18, 2022
Drug: Acetylsalicylic acid; Low Molecular Weight Heparin (LMWH) · For: Blood Clot; Trauma
Sites: Tucson, Arizona; Miami, Florida; Indianapolis, Indiana · 21 sites in all
- Thromboprophylaxis in Lower Limb ImmobilisationPivotal-lookingRecruiting
Queen Mary University of LondonAcademic, hospital or other
NCT06370273 · 10,044 participants (planned) · Start Nov 12, 2024 · Primary completion Aug 31, 2028
Drug: Rivaroxaban; Apixaban and 4 more · For: Thrombosis; Injury Leg
Sites: Carshalton, United Kingdom; Hull, United Kingdom; London, United Kingdom · 5 sites in all
- Short-term Low-dose Low-molecular-weight Heparin to Prevent Postpartum ThrombosisPivotal-lookingRecruiting
Marc BlondonAcademic, hospital or other
NCT07140211 · 9,200 participants (planned) · Start Oct 15, 2025 · Primary completion Aug 2030
Drug: Low-dose low-molecular-weight heparin · For: Venous Thromboembolism (VTE); Postpartum
Sites: Baden, Switzerland; Basel, Switzerland; Bern, Switzerland · 9 sites in all
- The PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue MorbidityPivotal-lookingRecruiting
University of CalgaryAcademic, hospital or other
NCT06494878 · 8,805 participants (planned) · Start Jun 4, 2026 · Primary completion Sep 2030
Drug: Aspirin; Low-molecular-weight heparin · For: Venous Thromboembolism; Postpartum Period; Aspirin and 1 more
Sites: Brussels, Belgium; Calgary, Canada; Ottawa, Canada · 12 sites in all
- Study to Evaluate the Mortality Reduction of Enoxaparin in Hospitalized Acutely Ill Medical Receiving EnoxaparinPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00622648 · 8,329 participants · Start Jan 2008 · Primary completion Dec 2010
Drug: Enoxaparin; Placebo · For: Acute Illness
Sites: São Paulo, Brazil; Shanghai, China; Hong Kong, Hong Kong · 9 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use2,665
- dyspnoea2,456
- nausea2,434
- diarrhoea2,330
- anaemia2,259
- thrombocytopenia2,131
- pyrexia2,098
- fatigue2,034
- vomiting1,905
- pulmonary embolism1,831
- death1,772
- pneumonia1,716
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1,257 |
| 2005 | 1,329 |
| 2006 | 1,244 |
| 2007 | 1,240 |
| 2008 | 1,501 |
| 2009 | 1,763 |
| 2010 | 1,941 |
| 2011 | 2,327 |
| 2012 | 2,297 |
| 2013 | 1,935 |
| 2014 | 2,315 |
| 2015 | 2,754 |
| 2016 | 2,904 |
| 2017 | 2,745 |
| 2018 | 3,649 |
| 2019 | 3,436 |
| 2020 | 3,596 |
| 2021 | 3,368 |
| 2022 | 3,956 |
| 2023 | 3,666 |
| 2024 | 3,309 |
| 2025 | 3,268 |
| 2026 | 2,249 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Lovenox (Enoxaparin Sodium)
2024 spending
$577K
Beneficiaries
392
950 claims
Per beneficiary
$1,471
$24.80 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $3,499,490 |
| 2021 | $2,848,286 |
| 2022 | $1,795,726 |
| 2023 | $675,990 |
| 2024 | $576,582 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Effect of Aspirin vs Enoxaparin on Symptomatic Venous Thromboembolism in Patients Undergoing Hip or Knee Arthroplasty: The CRISTAL Randomized Trial.
Sidhu VS, Kelly TL, Pratt N, et al. · JAMA 2022 · Comparative Study, Multicenter Study
- Abelacimab for Prevention of Venous Thromboembolism.
Verhamme P, Yi BA, Segers A, et al. · N Engl J Med 2021 · Comparative Study, Randomized Controlled Trial
- Enoxaparin for COVID-19: a systematic review and meta-analysis of randomized controlled trials.
Ehsan M, Jafar U, Butt M, et al. · J Thromb Thrombolysis 2023 · Meta-Analysis, Systematic Review
- Efficacy and safety of REGN9933A2 and REGN7508Cat for preventing postoperative venous thromboembolism (ROXI-VTE-I and ROXI-VTE-II): two randomised, open-label, phase 2 trials.
Weitz JI, Kithcart AP, O'Brien MP, et al. · Lancet 2025 · Randomized Controlled Trial, Clinical Trial, Phase II
- VenaFlow plus Lovenox vs VenaFlow plus aspirin for thromboembolic disease prophylaxis in total knee arthroplasty.
Westrich GH, Bottner F, Windsor RE, et al. · J Arthroplasty 2006 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Factor XI Inhibitors in Early Clinical Trials: A Meta-analysis.
Galli M, Laborante R, Ortega-Paz L, et al. · Thromb Haemost 2023 · Systematic Review, Meta-Analysis
Sponsor: Sanofi
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.